Protocol for the Tessa Jowell BRAIN MATRIX Platform Study

Colin Watts(Cancer Research UK Clinical Trials Unit), Victoria Wykes(University Hospitals Birmingham NHS Foundation Trust), Joshua Savage(Cancer Research UK Clinical Trials Unit), John Apps(Cancer Research UK Clinical Trials Unit), Rhys Mant(Cancer Research UK Clinical Trials Unit), Helen Bulbeck(Entrust), Rowena Sharpe(Cancer Research UK Clinical Trials Unit), Adam Waldman(Royal Society of Edinburgh), Ute Pohl(University Hospitals Birmingham NHS Foundation Trust), Olaf Ansorge(John Radcliffe Hospital), Gerard Thompson(University of Edinburgh), Lucinda Billingham(University Hospitals Birmingham NHS Foundation Trust), Amit Patel(Cancer Research UK Clinical Trials Unit)
medRxiv
July 31, 2022
10.1101/2022.07.29.22277991
Cited by 2

Related Papers

Incident dementia and blood pressure lowering in the Hypertension in the Very Elderly Trial cognitive function assessment (HYVET-COG): a double-blind, placebo controlled trial
|The Lancet Neurology|2008|774
Response assessment in neuro-oncology (a report of the RANO group): assessment of outcome in trials of diffuse low-grade gliomas
|The Lancet Oncology|2011|649
Aging-related tau astrogliopathy (ARTAG): harmonized evaluation strategy
|Acta Neuropathologica|2015|528
Mitomycin, Ifosfamide, and Cisplatin in Unresectable Non–Small-Cell Lung Cancer: Effects on Survival and Quality of Life
|Journal of Clinical Oncology|1999|449
Long-term safety and tolerability of ProSavin, a lentiviral vector-based gene therapy for Parkinson's disease: a dose escalation, open-label, phase 1/2 trial
|The Lancet|2014|436